Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article discusses a study linking tamsulosin treatment for benign prostatic hyperplasia to a small but statistically significant increase in dementia risk compared to other treatments, without presenting new results.

This narrative review discusses the mixed and evolving evidence regarding glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and their influence on erectile dysfunction in men with type 2 diabetes and obesity, highlighting potential benefits and concerns yet to be clarified.

This review explores different types of alopecia, the effects on hair appearance and growth, and the conventional treatments available, including minoxidil and finasteride, along with their side effects and the need for future drug development and potential therapies.

This study found that both a proprietary ultrahigh-pressure extract and a hexanic extract of saw palmetto showed comparable inhibition of 5α-reductase, suggesting similar potential for managing symptoms of benign prostatic hyperplasia.

This review assesses the potential of dutasteride as a promising treatment for ALS due to its reported neuroprotective, antioxidant, and anti-inflammatory effects, but emphasizes that clinical studies are needed for confirmation.

Fat-derived stem cell therapies can potentially increase hair growth and thickness in people with hair loss.

Fat-derived stem cell therapies can potentially increase hair growth and thickness in people with hair loss.

This review discusses the off-label use of SSRIs to manage inappropriate sexual behavior in elderly dementia patients and highlights the unclear risk of post-SSRI sexual dysfunction, noting a need for high-quality clinical trials.

This retrospective pharmacovigilance study identified 34 drugs, including finasteride and dutasteride, that may be associated with sexual dysfunction, with a higher risk observed in males aged 31-45.

In this study, the researchers reconstructed Abraham's family pedigree from the Bible's book of Genesis to explore potential medical or genetic explanations for reported cases of familial infertility, linking historical accounts with plausible scientific reasoning.

This study found that 1′S-1′-acetoxychavicol acetate from Alpinia galanga inhibits Nox isozymes and suppresses testosterone-induced hair loss in a mouse model of androgenetic alopecia.

In this study, the researchers found that the water-soluble fraction of Rhus semialata gall extract and its component Penta-O-Galloyl-β-D-Glucose promoted hair growth in human dermal papilla cells, and clinical trials supported these findings, showing improved hair density and appearance compared to placebo.

This study found that extracellular vesicles derived from hyaluronic acid-stimulated induced pluripotent stem cells significantly improved hair growth in a model of androgenetic alopecia in mice by enhancing Wnt/β-catenin signaling and regulating androgen receptor activity, showing comparable results to the commonly used treatment finasteride.

Hemp seed biomaterials may reduce hair loss and improve hair growth.

This research used computational methods to identify potential new treatments for benign prostatic hyperplasia, finding three compounds from Ghanaian plants with promising binding energy against 5alpha reductase 2 compared to existing drugs, yet further in vitro validation is necessary to confirm their efficacy.

This study found that topical finasteride mixed with minoxidil improved hair appearance and self-esteem in men with androgenetic alopecia, but it was not superior to oral finasteride and had lower treatment adherence.

This study found that the topical Shen Bai hair growing decoction may improve androgenetic alopecia in mice by suppressing TNF-α and IL-6 levels, enhancing follicle density, and reducing apoptosis.

The authors concluded that the concept of postfinasteride syndrome remains contentious and may be more plausibly characterized as a psychiatric condition rather than a consistent medical syndrome.

This study investigated medications potentially linked to male-factor infertility using the FDA Adverse Event Reporting System and found that finasteride, testosterone, valproate, and other drugs showed significant disproportionate reporting of infertility cases, highlighting a potential under-reporting issue to regulatory bodies.

This review concluded that the efficacy of cosmeceutical hair serums for addressing hair loss lies in their use of bioactive peptides and plant compounds, like flavonoids and sterols, that target eight key contributing factors identified in hair loss conditions.

This review discusses the potential impact of COVID-19 on the male reproductive system and highlights unanswered questions regarding its mechanisms and implications for men's health and fertility, reporting no new clinical results.

This study found that users of a German direct-to-consumer teledermatology platform for finasteride reported improvements in hair appearance and self-esteem, though 12% experienced treatment-related adverse events.

This review summarizes existing knowledge on diffuse and patterned alopecia, emphasizing recent advancements in treatment beyond FDA-approved options, but it reports no new clinical findings.

BPH treatment improved with personalized medicine, new drugs, and less invasive surgeries.

This article discusses the various administration methods and considerations for testosterone replacement therapy, highlighting the importance of individualized therapeutic monitoring and potential adverse effects, but reports no new clinical results.

This study found a high discontinuation rate of topical minoxidil among patients with androgenetic alopecia, largely influenced by short treatment duration, lack of efficacy, and adverse effects.

This review discusses current and emerging therapies for androgenetic alopecia, emphasizing regenerative treatments and nanotechnology advancements, but it reports no new clinical results.

This review discusses recent research on male infertility causes and treatments, emphasizing the need for further understanding of idiopathic sperm abnormalities and molecular factors to improve patient outcomes; it reports no new clinical results.

The conclusion is that women under 35 should start fertility checks after 12 months of trying to conceive, women over 35 after 6 months, and women over 40 should start immediately. The checks should include ovulation status, reproductive tract structure, and male partner's semen evaluation.